ARYLATION OF MGMT BY PARP IS REQUIRED FOR MGMT MEDIATED TEMOZOLOMIDE-INDUCED O6-METHYLGUANINE REPAIR: A NOVEL MECHANISM OF MGMT ACTION

被引：0
|
作者：
Wu, Shaofang [1 ]
Gao, Feng [1 ]
Koul, Dimpy [1 ]
Yung, Alfred [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DRES-02
引用
收藏
页码：71 / 72
页数：2
相关论文
共 50 条
  • [41] Inhibition of O6-methylguanine-DNA-methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT-proficient cells
    Akcora-Yildiz, Dilara
    Ozkan, Tulin
    Cetintav, Bekir
    Yukselten, Yunus
    Calis, Seyma
    Sevim-Nalkiran, Hatice
    Turkel, Nezaket
    Gunduz, Mehmet
    Ozen, Mehmet
    Beksac, Meral
    Sunguroglu, Asuman
    CHEMICAL BIOLOGY & DRUG DESIGN, 2024, 103 (02)
  • [42] O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
    Polozkova, S.
    Stepanova, E.
    Delektorskaya, V.
    Kozlov, N.
    Gorbunova, V.
    Orel, N.
    Markovich, A.
    Kuzminov, A.
    Emelianova, G.
    Odintsova, A.
    NEUROENDOCRINOLOGY, 2016, 103 : 71 - 72
  • [43] Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine
    Roos, W. P.
    Batista, L. F. Z.
    Naumann, S. C.
    Wick, W.
    Weller, M.
    Menck, C. F. M.
    Kaina, B.
    ONCOGENE, 2007, 26 (02) : 186 - 197
  • [44] The temozolomide O6-methylguanine-DNA methyltransferase (MGMT) study: A phase II trial to evaluate the effect of low-dose preoperative neoadjuvant temozolomide on brain tumour MGMT activity in glioma patients
    Del Maestro, R. F.
    Siu, V.
    Sadr, M. Seyed
    Alshami, J.
    Sabau, C.
    Sadr, E. Seyed
    Samani, A.
    Assadian, S.
    Greaves, K.
    Pouliot, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
    Weller, M.
    Gramatzki, D.
    Felsberg, J.
    Hentschel, B.
    Wolter, M.
    Schackert, G.
    Westphal, M.
    Regli, L.
    Thon, N.
    Tatagiba, M.
    Wick, W.
    Schlegel, U.
    Krex, D.
    Roth, P.
    Rushing, E.
    Pietsch, T.
    von Deimling, A.
    Sabel, M.
    Loeffler, M.
    Reifenberger, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S396 - S396
  • [46] The P14oK mutant of human O6-methylguanine-DNA-methyttransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl)guanine
    Woolford, LB
    Southgate, TD
    Margison, GP
    Milsom, MD
    Fairbairn, LJ
    JOURNAL OF GENE MEDICINE, 2006, 8 (01): : 29 - 34
  • [47] O6-Methylguanine-DNA Methytransferase (MGMT) Immunohistochemistry as a Predictor of Resistance to Temozolomide in Primary CNS Lymphoma.
    Jiang, X.
    Reardon, D. A.
    Desjardins, A.
    Vredenburgh, J. J.
    Quinn, J. A.
    Austin, A. D.
    Herndon, J. E.
    McLendon, R. E.
    Friedman, H. S.
    MODERN PATHOLOGY, 2011, 24 : 382A - 382A
  • [48] Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma
    Jin, Lei
    Kiang, Karrie Mei-Yee
    Cheng, Stephen Yin
    Leung, Gilberto Ka-Kit
    LABORATORY INVESTIGATION, 2022, 102 (02) : 194 - 203
  • [49] A study of clinico-pathological parameters and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma
    Singh, Geetika
    Mallick, Supriyo
    Sharma, Vikas
    Joshi, Nikhil
    Purkait, Suvendu
    Jha, Prerana
    Sharma, Mehar Chand
    Suri, Vaishali
    Julka, Pramod Kumar
    Mahapatra, Ashok Kumar
    Singh, Manmohan
    Kale, Shashank Sharad
    Sarkar, Chitra
    NEUROPATHOLOGY, 2012, 32 (05) : 534 - 542
  • [50] O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki67 Index Predict Response to Temozolomide in Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)
    Cros, Jerome
    Hentic-Dhome, Olivia
    Rebours, Vinciane
    Zappa, Magaly
    Maire, Frederique
    Hammel, Pascal
    Levy, Philippe
    Ruszniewski, Philippe
    Couvelard, Anne
    GASTROENTEROLOGY, 2014, 146 (05) : S74 - S74
12345